Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Inclusion Criteria: * HBsAg positive and anti-HBs negative for more than 6 months * HBeAg positive * HBV DNA titer more than 100,000 IU/mL * serum ALT more than upper normal limit value, but no more than 10 times upper normal limit value Exclusion Criteria: * the history of antiviral therapy for chronic hepatitis B within the recent 6 months * HAV IgM Ab + and/or HCV Ab + and/or HDV Ab and/or HIV Ab + * the sign of decompensated liver disease * the history of hemoglobinopathy, autoimmune hepatitis, alcoholic liver disease * pregnant or lactating woman * neutrophil count less than 1,500/mm3 or platelet count less than 90,000/mm3 * serum creatinine more than 1.5 times upper normal limit value * the sign of alcoholic or drug addiction within the recent 1 year * the history of psychotic disorder especially like depression * immunologically mediated disease * the history of esophageal varix * the history of severe heart disease or respiratory disease * the history of severe epilepsy or current use of antiepileptic drug * the sign of malignancy or suggestive of malignancy or the history of malignancy, the recurrence rate within 2 years of which is more than 20% * the history of systemic anticancer treatment including radiation therapy or immunotherapy including systemic corticosteroid * the history of major organ transplantation * the history of medically uncontrolled thyroid disease * the history or sign of severe retinopathy